Ovarian cancer is highly lethal, largely due to the rapid development of paclitaxel resistance...RNA pull-down, RNA immunoprecipitation (RIP), and actinomycin D mRNA decay assays were conducted to elucidate the molecular interactions between lncRNA-PRLB, the RNA-binding protein fused in sarcoma (FUS), and glutathione peroxidase 4 (GPX4) mRNA...This study identifies lncRNA-PRLB as a critical upstream regulator of ferroptosis resistance and chemoresistance in ovarian cancer. By scaffolding FUS to stabilize GPX4 mRNA, lncRNA-PRLB maintains GPX4 expression and enables tumor cells to evade ferroptotic cell death.

The Actinomycin D and dual-luciferase reporter assays confirmed that YTHDF1 can affect the stability of LRP5 mRNA. Further in vitro experiments indicated that YTHDF1 knockdown reduces the protein levels of key Wnt pathway components and inhibits the cell malignant phenotype, while LRP5 overexpression reverses the effects induced by YTHDF1 knockdown. In conclusion, YTHDF1-mediated RNA m1A modifications facilitate the malignant progression of HCC by modulating the LRP5/Wnt/β-catenin signaling pathway.

Non-targeted metabolomics analysis using LC-MS identified specific activation of the histidine metabolism pathway, with elevated levels of the key metabolite Cetirizine N-Oxide potentially contributing to enhanced immune activity. Mechanistic studies further revealed that the triple therapy suppresses the activity of the Bcl6 regulatory network, thereby reducing the immunosuppressive function of Tregs and destroying the immunosuppressive interplay between myeloid immune cells and Tregs. These results demonstrate a promising "microbiome-immune" dual-targeting strategy for colon cancer with clinical translational potential.

A double-J ureteral stent was placed, and systemic therapy with vincristine, actinomycin D, and cyclophosphamide (VAC) was initiated. This case highlights a brisk response of disseminated intratesticular rhabdomyosarcoma to VAC chemotherapy and supports comprehensive staging and response-adapted multidisciplinary management. The complete case-level extraction and full citations are provided in the Supplementary material.

P3, N=808, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Mar 2026

This report describes the case of a 7-year-old child with ALL who developed paronychia following combination chemotherapy with vincristine and daunorubicin...A structured, multistep nursing protocol was implemented, including local disinfection, ethacridine lactate compresses, topical application of recombinant human epidermal growth factor solution and mupirocin ointment, and local oxygen insufflation...This case highlights the importance of early recognition of chemotherapy-induced skin toxicity and the value of standardized stepwise wound management in improving functional outcomes. It provides a practical reference for managing this rare yet severe cutaneous adverse reaction in children and underscores the critical role of specialized nursing in supportive oncology care.

RNase R digestion and actinomycin D assays were employed to assess its stability...Animal experiments confirmed that silencing circ_0017521 suppressed tumor growth and glycolysis. This study revealed that hypoxia-induced circ_0017521 activated the PI3K/AKT pathway through the miR-532-3p/PFKFB3 axis, synergistically driving EMT and glycolysis, thereby promoting NSCLC progression.

Functionally, COR treatment inhibited EVT cell invasion, and this effect was mediated by MMP2 downregulation. These findings provide new insights into the molecular mechanisms by which COR regulates EVT cell invasiveness and highlight the potential implications of COR as a health supplement during pregnancy.

P4, N=100, Not yet recruiting, Boston Children's Hospital | Trial completion date: Dec 2028 --> Dec 2039 | Trial primary completion date: Dec 2028 --> Dec 2035

The relationship between SERPINF1 and FTO was determined through correlation analysis, methylated RNA immunoprecipitation, luciferase, RT-qPCR, Western blotting, RNA immunoprecipitation, and actinomycin D treatment assays...Rescue experiments demonstrated that SERPINF1 overexpression reversed FTO-induced oncogenic phenotypes. These findings suggest that FTO-mediated m6A demethylation suppressed SERPINF1 expression in MM, whereas SERPINF1 overexpression inhibited tumor progression via the Wnt/β-catenin pathway.

Functional validation using actinomycin D and cycloheximide treatments demonstrated that compound 2 suppresses RPL27A and RPLP0 expression at the translational level, thereby inhibiting tumor cell invasion and migration and exerting robust antitumor effects. Collectively, these findings provide novel insights into the anticancer mechanisms of EEF1A1-targeting agents and highlight EEF1A1 as a promising therapeutic target for the treatment of TNBC.

The WTAP/TP53BP1 axis impairs periodontal tissue regeneration by promoting P-PDLSC senescence and suppressing osteogenic differentiation in an m6A-dependent manner, revealing a new cellular-level target for treating periodontitis.